Orelabrutinib with or without Anti-CD20 Monoclonal Antibodies Is Highly Effective and Well Tolerated As First-Line Therapy for Marginal Zone B Cell Lymphoma
第一作者机构：[1]Beijing Tongren Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Yao Na,Li Xin,Yang Jing,et al.Orelabrutinib with or without Anti-CD20 Monoclonal Antibodies Is Highly Effective and Well Tolerated As First-Line Therapy for Marginal Zone B Cell Lymphoma[J].BLOOD.2024,144:6541-6542.doi:10.1182/blood-2024-203548.
APA：
Yao, Na,Li, Xin,Yang, Jing,Cong, Jia&Wang, Liang.(2024).Orelabrutinib with or without Anti-CD20 Monoclonal Antibodies Is Highly Effective and Well Tolerated As First-Line Therapy for Marginal Zone B Cell Lymphoma.BLOOD,144,
MLA：
Yao, Na,et al."Orelabrutinib with or without Anti-CD20 Monoclonal Antibodies Is Highly Effective and Well Tolerated As First-Line Therapy for Marginal Zone B Cell Lymphoma".BLOOD 144.(2024):6541-6542
医学